T he diverse spectrum of primary immunodeficiencies includes more than 250 rare chronic diseases that affect both innate and adaptive immunity. Gastrointestinal manifestations can be the primary presentation of immune deficiencies, including diarrhea, malabsorption, abdominal pain, and inflammatory bowel disease (IBD). 1 Gastrointestinal tract involvement and symptoms in immunodeficiency are not surprising because the intestinal tract contains the largest mass of lymphoid tissue, and the mucosa is at the interface of host-microbe interactions. The mucosal immune system requires a tightly controlled balance between tolerance of commensal microbes and detection and response against pathogens. Rare monogenic defects in immune pathways have been identified in very young patients with IBD, known as very early onset IBD (VEO-IBD), diagnosed in children who present with symptoms by the age of 5 years. 2, 3 VEO-IBD is a heterogeneous disorder with a subset of patients who present with severe disease, often refractory to conventional medical therapies compared with older onset IBD. The increased utilization of whole-exome sequencing (WES) has identified several novel variants in immune pathways that are associated with this phenotype, and there are now more than 50 monogenic defects detected in patients with severe VEO-IBD. 4, 5 In this study, we present a novel mutation in ZBTB24, the gene responsible for immunodeficiency, centromere instability, and facial anomalies type-2 syndrome (ICF2, OMIM #614064), detected by WES in a child with VEO-IBD. This is the first report of IBD associated with this syndrome.
METHODS
A 17-month-old boy initially presented with several months of poor weight gain and linear growth, recurrent fevers, constipation, and intermittent blood in his stool. Pertinent family history included multiple layers of consanguinity and Crohn's disease in his maternal grandmother. His physical examination was notable for hypertelorism, epicanthal folds, low-set posteriorly rotated ears, developmental delay, and perianal fistula on rectal examination. Colonoscopy revealed multiple ulcerations in descending colon and rectum. The histologic examination showed active chronic colitis with crypt architectural distortion. He was initially treated with azathioprine, corticosteroids, mesalamine enemas, and metronidazole and had resolution of his symptoms and fistula within 6 months. He subsequently developed serious infections, including multiple episodes of febrile pneumonia requiring hospitalizations and treatment with intravenous antibiotics. Additionally, he had 2 episodes of acute otitis media but no sinusitis or cellulitis, and his growth remained poor.
He underwent clinical immune workup including evaluation of his B cells, T cells, natural killer cells, immunoglobulins, and vaccine titers. Under protocol 2014-010826 approved by the Children's Hospital of Philadelphia Institutional Review Board, genomic DNA was obtained from the child and his parents. The Agilent SureSelect Clinical Research Exome kit, targeting the coding exonic regions of the genome, was used for library preparation. Sequencing was performed using the Illumina HiSeq 2000 with 100-base pair, paired-end reads. Sequence data were assembled and aligned to the reference human genome browser GRCh37/UCSC hg19 using Novoalign (V3.03.01; http://www. novocraft.com). Sequence variants were identified using GATK's best practices and annotated for allele frequencies using the reference databases (1000 Genomes Project, ESP, and ExAC) and known disease variants using the Human Genome Mutation Database and ClinVar of the National Center for Bintechnology Information. 6, 7 Analysis for the patient included evaluating variants that are de novo, compound heterozygous, homozygous, and X linked. Identified variants were filtered for rare (minor allele frequency , 1%) or novel missense, nonsense, and frameshift mutations and restricted to genes involved in primary immunodeficiency and IBD based on the clinical phenotype.
DNA obtained from the patient, his parents, and a patient with VEO-IBD without a mutation in ZBTB24 were bisulfite converted and hybridized to the Illumina HumanMethylation450 BeadChip array using the Infinium HD Methylation protocol (Illumina, San Diego, CA). Beta values representing the level of methylation of a probe were obtained using Genome Studio. bvalues range from 0 (completely unmethylated) to 1 (methylated). Data were processed using the Illumina Methylation Analyzer package in R. 8 Briefly, sites containing missing values were removed, peak correction was performed, and the data were quantile normalized. Probes with a detection P value of . 0.05 and those containing single-nucleotide polymorphisms were removed from further analysis. A total of 392,222 probes passed quality control. Alpha satellite region coordinates were obtained from the USCS Genome Browser to identify probes within these regions.
Differentially methylated probes were identified as those with a bvalue difference of .j0.2j in the patient compared with the 2 healthy parents.
RESULTS
Immune workup revealed a combined immunodeficiency including total hypogammaglobulinemia, decreased production and maturation of B cells, decreased natural killer cells, and poor titer response to vaccines (Table 1) .
WES detected a potential causative homozygous frameshift mutation, c.1492-1493delCA: p.Gln498ValfsX15, in ZBTB24, which is involved in B-cell differentiation and has previously been associated with ICF2, characterized by facial anomalies, developmental delay, and recurrent respiratory and gastrointestinal infections due to a multifactorial immunodeficiency. The patient's mother and father are healthy and heterozygous for the same mutation. Karyotype revealed chromosomal changes due to centromere instability in 1q, 9q, and 16q, including heterochromatin decondensation and stretching, multiradial configurations, and deletions, which are unique features of immunodeficiency, centromere instability, and facial anomalies (ICF) and confirmed this diagnosis (Fig. 1) . More extensive evaluation of his intestinal biopsies revealed a hypocellular lamina propria in the duodenum that had minimal CD79a histochemical staining of a few scattered plasma cells and absent immunohistochemical staining for both immunoglobulin A-producing and immunoglobulin G-producing plasma cells in comparison with another VEO-IBD patient without the ZBTB24 mutation ( Fig. 2A, B) .
Additionally, a homozygous variant of unknown significance in IL7R (c.419 G.A:p.Arg140Gln) was detected by WES in the child and confirmed heterozygous in both parents. This gene has been previously associated with a severe form of combined immunodeficiency that is defined by the absence of mature T cells and the presence of B cells and natural killer cells. These findings were not consistent with this patient's immune profile, and the variant was not novel. There were no variants in the genes known to be associated with the adult-onset form of IBD.
Prior work described distinctive methylation defects in patients with ICF type-1 syndrome; thus, methylation analyses were performed in this patient. 9 A total of 15 probes overlapped alpha satellite regions obtained from the UCSC Genome Browser, including 8 probes on chromosome 1 and none on chromosomes 9 and 16. Three of the 15 probes (20%) were unmethylated in the patient compared with his healthy parents, including 1 probe on each of chromosomes 7, 10, and 18. None of the probes were hypermethylated in the patient compared with his parents. Despite the small number of alpha satellite regions represented, there was a significant representation of hypomethylated probes in the patient (P ¼ 4 · 10 23 ). A similar analysis in a VEO-IBD patient without any mutations in ZBTB24 did not result in any differentially methylated probes within the alpha satellite regions.
DISCUSSION
Monogenic defects of primary immunodeficiencies involving B-and T-cell abnormalities, phagocyte defects, epithelial barrier defects, and autoimmunity can present as VEO-IBD. 10 In this patient with IBD and recurrent infections, the immunologic workup was concerning for hypogammaglobulinemia, and WES revealed a homozygous novel frameshift variant in ZBTB24, consistent with a diagnosis of ICF2. Up to 13 homozygous and compound heterozygous mutations of ZBTB24 have been described in patients with this syndrome, characterized by fragile heterochromatin resulting in unstable chromosomes, which is associated with immunodeficiency, most commonly hypogammaglobulinemia or agammaglobulinemia, facial anomalies including hypertelorism, flat nasal bridge, epicanthal folds, micrognathia, and tongue protrusion, and variable intellectual disability. 11, 12 IBD confirmed by endoscopic biopsy has not previously been reported with ICF2, but IBD has been associated with other humoral immunodeficiencies defined by hypogammaglobulinemia or agammaglobulinemia. This association has led to the use of intravenous immunoglobulin as a therapy for IBD in some refractory cases.
There are currently 5 subtypes of ICF syndrome, all phenotypically very similar, and ICF types 1 to 4 compose 80% of all cases. About half of ICF cases are due to mutations in DNA methyltransferase 3B gene (DNMT3B), which is involved in de novo DNA methylation resulting in ICF type-1 syndrome, and 30% of all cases are due to mutations in ZBTB24, which encodes a protein involved in the methylation of juxtacentromeric DNA resulting in ICF2. Recent advances in the investigation of those cases of ICF without known gene defects have identified cell division cycle associated 7 (CDCA7) and helicase lymphoid specific (HELLS) as the causative genes in ICF type-3 and type-4 syndromes. 13 The remaining cases with thus far unknown genetic mutations are known as ICFX.
ZBTB24 is a member of the zinc-binding and BTBdomain-binding family of transcription factors, some of which are involved in hematopoietic development, differentiation, and function. Interestingly, the immune dysregulation in ZBTB24 deficiency resembles the phenotype of ZBTB27 mutations. ZBTB27, also known as BCL-6, is necessary for germinal center structures, generation of B cells, and production of antibodies. Immunophenotyping of patients with ZBTB24 mutations, including our patient, reveals similar defects in circulating memory B cells. Liang et al 14 demonstrated that ZBTB24 is a novel transcription factor involved in human B-cell proliferation and differentiation. These functions are mediated through IRF-4 and BLIMP-1. This essential role in B cells secondary to the reduced proliferation of germinal center B cells results in the phenotype of reduced serum immunoglobulins and memory B cells as seen in our patient.
Previously reported nonsense mutations in ZBTB24 were associated to hypomethylation of centromeric alpha-satellites and juxtacentromeric satellite repeats. This results in the characteristic multibranching of long arms of chromosomes 1, 9, and 16, causing radial chromosomes. A cause for the structural abnormalities only in these chromosomes has yet to be elucidated. For this patient, we demonstrated that there was a significantly increased number of hypomethylation probes in the alpha satellite regions compared with his healthy parents and another child with VEO-IBD without mutations in ZBTB24. The association of this defect with IBD remains to be explained and warrants further studies. This is the first report of VEO-IBD in association with homozygosity for a novel mutation in ZBTB24, consistent with the diagnosis of ICF2. Primary immunodeficiencies can present with phenotypic characteristics of VEO-IBD and other autoimmune disorders. The intestinal phenotype of IBD is likely secondary to the overall immune dysregulation in this patient. Here, WES together with immunophenotyping detected a novel variant in a known immunodeficiency gene that presented as recurrent pneumonia and IBD. Following the identification of the ZBTB24 gene defect and clinical finding of hypogammaglobulinemia, the patient was treated with intravenous immunoglobulin monthly and was able to successfully induce and maintain remission and also avoid further recurrent infections during the period of follow-up.
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